title: Expression of Epstein-Barr nuclear antigen 2 in kidney tubule cells induce tumors in transgenic mice.
abstract: The effect of EBNA2 in normal cells in vivo has not as yet been explored. The experiments described here were initiated to follow the consequences of the expression of EBNA2 in different tissues in transgenic mice. EBNA2 transgenic strains were generated using a vector containing EBNA2 encoding sequences under the control of the simian virus 40 (SV 40) early enhancer/promoter fused to the endogenous EBNA2 Wp promoter. Control mice carrying a transgene with the same sequence but lacking the EBV DNA part remained healthy during observation periods of up to 15 months. The SV-EBNA2 transgenic animals, however, over time developed abdominal masses that on necropsy showed to be due to kidney tumors. Histological examination revealed the presence of tumors with the morphology of kidney adenocarcinoma with a solid growth pattern. At the age of 20 weeks the kidneys of all animals investigated showed disseminated islands of tubular hyperplasia but no true malignant neoplasms. At about 50 weeks of age multiple foci of microscopic tubular adenocarcinomas were found in both kidneys. Eventually, tumors could be diagnosed in about 90% of the SV-EBNA2 transgenic mice. EBNA2-encoding RNA was expressed in both non-malignant kidney tissue and in tumors as shown by cDNA/PCR analysis. Immunoprecipitation and immunoblot analysis showed that the tumor cells contained a polypeptide of the same size as EBNA2 in B95-8 cells that reacted with a monoclonal anti-EBNA2 antibody. Immunohistochemistry demonstrated nuclear expression of EBNA2 in hyperplastic tubules and in tumor tissue.
authors.affiliation: Department of Physiology and Pharmacology, Göteborg University, Gothenburg, Sweden.
authors.forename: J
authors.initials: J
authors.lastname: Törnell
authors.forename: S
authors.initials: S
authors.lastname: Farzad
authors.forename: A
authors.initials: A
authors.lastname: Espander-Jansson
authors.forename: G
authors.initials: G
authors.lastname: Matejka
authors.forename: O
authors.initials: O
authors.lastname: Isaksson
authors.forename: L
authors.initials: L
authors.lastname: Rymo
mesh_terms: D000230:Adenocarcinoma / Q000276:immunology*; D000818:Animals; D000956:Antigens, Viral / Q000235:genetics*; D001483:Base Sequence; D017931:DNA Primers; D004268:DNA-Binding Proteins / Q000235:genetics*; D019309:Epstein-Barr Virus Nuclear Antigens; D007680:Kidney Neoplasms / Q000276:immunology*; D007686:Kidney Tubules, Distal / Q000166:cytology / Q000378:metabolism*; D051379:Mice; D008810:Mice, Inbred C57BL; D008808:Mice, Inbred CBA; D008811:Mice, Inbred DBA; D008822:Mice, Transgenic; D008969:Molecular Sequence Data; D011230:Precancerous Conditions / Q000235:genetics; D011401:Promoter Regions, Genetic; D012333:RNA, Messenger / Q000235:genetics; D013160:Splenic Neoplasms / Q000235:genetics; D019076:Transgenes
chemical_list: D000956:Antigens, Viral; D017931:DNA Primers; D004268:DNA-Binding Proteins; D019309:Epstein-Barr Virus Nuclear Antigens; D012333:RNA, Messenger